acute coronary syndrome
Cardiovascular · 2008–2024
6decisions
3medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| prasugrel Treatment of acute coronary syndrome (myocardial infarction or unstable angina) managed by percutaneous coronary intervention (PCI), in combination with… | Jul 2024 | Recommended | none received |
| prasugrel Acute coronary syndrome (myocardial infarction or unstable angina) managed by percutaneous coronary intervention (PCI), in combination with aspirin. | Mar 2024 | Not recommended | input received |
| ticagrelor Treatment of acute coronary syndrome (ACS) in combination with aspirin for the prevention of atherothrombotic events (cardiovascular death, myocardial… | Mar 2023 | Not recommended | none received |
| ticagrelor Treatment of acute coronary syndromes (myocardial infarction or unstable angina) in combination with aspirin. | Jul 2011 | Recommended | no section in document |
| prasugrel treatment of acute coronary syndromes (myocardial infarction or unstable angina) in combination with aspirin in patients who are to undergo percutaneous… | Jul 2009 | Recommended with restriction | no section in document |
| clopidogrel hydrogen sulfate Treatment of acute coronary syndromes (myocardial infarction or unstable angina) in combination with aspirin to prevent early and long-term atherothrombotic… | Mar 2008 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.